Transplantation, encompassing both hematopoietic stem cell and solid organ transplants, is a critical medical intervention for treating various life-threatening conditions. However, it is often complicated by alloantigen-induced immune activation, a response triggered by the donor’s immune system against recipient antigens and/or the recipient's immune system against donor antigens. This immune activation can arise from prior sensitization events such as blood transfusions, previous transplants, or fetal-maternal interactions. While alloantigen-induced immune responses can be beneficial, as seen in the Graft vs. Leukemia (GvL) or Graft vs. Tumor (GvT) effects, they can also lead to adverse outcomes like Graft vs. Host Disease (GvHD) and graft rejection. Several studies have highlighted the complex interactions between immune cell populations in these processes, emphasizing the need for therapeutic strategies that balance long-term donor-recipient tolerance with the preservation of anti-tumor immunity and protection against opportunistic infections. Despite advancements, there remains a significant gap in understanding the molecular and cellular dynamics of alloantigen-induced immune activation, necessitating further research to develop more effective and tailored therapeutic approaches.
This research topic aims to explore and delineate both molecular and cell-based therapeutic strategies designed to control the adverse effects of alloantigen-specific immune responses while maintaining anti-tumor immunity and protection against opportunistic infections in transplant recipients. It encompasses a critical review of existing therapeutic modalities, evaluates the latest advancements, and highlights ongoing research focused on refining these strategies. The objective is to foster a comprehensive understanding of the immune mechanisms at play and to identify innovative approaches that can enhance transplant outcomes.
To gather further insights in the complex interplay of immune responses in transplantation, we welcome articles addressing, but not limited to, the following themes:
- Enhancing anti-tumor and antivirus immune surveillance in the context of transplantation
- Understanding the biological mechanisms underpinning alloreactive immune responses
- Investigating transplantation's role in autoimmune diseases and immune regulatory disorders
- Examining the contributions of innate immunity, T lymphocyte-mediated immunity, humoral immunity, T-regulatory cells, and B-regulatory cells to transplant outcomes
- Evaluating the impact of mesenchymal stromal cells in fostering donor/recipient tolerance
- Evaluating the role of trained immunity and dendritic/APC in the anti-tumor defense
- Assessing the efficacy of current and emerging molecular and cell-based therapies in transplantation settings
Manuscripts may include original research, reviews, case studies, opinions, perspectives, study protocols, and methodological papers that contribute significantly to our understanding of these areas. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Transplantation, encompassing both hematopoietic stem cell and solid organ transplants, is a critical medical intervention for treating various life-threatening conditions. However, it is often complicated by alloantigen-induced immune activation, a response triggered by the donor’s immune system against recipient antigens and/or the recipient's immune system against donor antigens. This immune activation can arise from prior sensitization events such as blood transfusions, previous transplants, or fetal-maternal interactions. While alloantigen-induced immune responses can be beneficial, as seen in the Graft vs. Leukemia (GvL) or Graft vs. Tumor (GvT) effects, they can also lead to adverse outcomes like Graft vs. Host Disease (GvHD) and graft rejection. Several studies have highlighted the complex interactions between immune cell populations in these processes, emphasizing the need for therapeutic strategies that balance long-term donor-recipient tolerance with the preservation of anti-tumor immunity and protection against opportunistic infections. Despite advancements, there remains a significant gap in understanding the molecular and cellular dynamics of alloantigen-induced immune activation, necessitating further research to develop more effective and tailored therapeutic approaches.
This research topic aims to explore and delineate both molecular and cell-based therapeutic strategies designed to control the adverse effects of alloantigen-specific immune responses while maintaining anti-tumor immunity and protection against opportunistic infections in transplant recipients. It encompasses a critical review of existing therapeutic modalities, evaluates the latest advancements, and highlights ongoing research focused on refining these strategies. The objective is to foster a comprehensive understanding of the immune mechanisms at play and to identify innovative approaches that can enhance transplant outcomes.
To gather further insights in the complex interplay of immune responses in transplantation, we welcome articles addressing, but not limited to, the following themes:
- Enhancing anti-tumor and antivirus immune surveillance in the context of transplantation
- Understanding the biological mechanisms underpinning alloreactive immune responses
- Investigating transplantation's role in autoimmune diseases and immune regulatory disorders
- Examining the contributions of innate immunity, T lymphocyte-mediated immunity, humoral immunity, T-regulatory cells, and B-regulatory cells to transplant outcomes
- Evaluating the impact of mesenchymal stromal cells in fostering donor/recipient tolerance
- Evaluating the role of trained immunity and dendritic/APC in the anti-tumor defense
- Assessing the efficacy of current and emerging molecular and cell-based therapies in transplantation settings
Manuscripts may include original research, reviews, case studies, opinions, perspectives, study protocols, and methodological papers that contribute significantly to our understanding of these areas. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.